What is the recommended management for a patient with clinical stage I seminoma after radical inguinal orchiectomy, including surveillance, adjuvant radiotherapy, and single‑dose carboplatin chemotherapy based on risk factors?

Stage I Seminoma: Surveillance is Preferred

Surveillance after radical inguinal orchiectomy is the recommended first-line management strategy for clinical stage I seminoma, with adjuvant single-dose carboplatin (AUC 7) as an acceptable alternative for patients with high-risk features (tumor size ≥4 cm and/or rete testis invasion) who prefer adjuvant treatment. 1, 2, 3

Why Surveillance is Preferred

All three management options—surveillance, adjuvant carboplatin, and adjuvant radiotherapy—achieve approximately 99% cancer-specific survival in stage I seminoma 4. Because cure is essentially guaranteed regardless of approach, minimizing treatment-related toxicity becomes the priority 4. Surveillance avoids unnecessary treatment in the 80-85% of patients who are already cured by orchiectomy alone 4, 5.

The relapse rate on surveillance is 15-20% at 5 years, with most relapses occurring in the retroperitoneum within the first 2-3 years 4, 2, 4. Critically, all relapses are salvageable with chemotherapy or radiotherapy, maintaining the near-perfect survival rate 1, 2.

Risk-Adapted Approach

Two risk factors predict higher relapse risk:

• Tumor size ≥4 cm
• Rete testis invasion

Patients with both risk factors have approximately 30-32% relapse risk, those with one factor have 15-16% risk, and those with neither have 12% risk 6, 7. However, the predictive value of these risk factors remains controversial and should not be the sole basis for treatment decisions 4, 1.

Adjuvant Carboplatin: The Alternative

For patients unwilling or unable to comply with surveillance, or those with both high-risk features who prefer adjuvant treatment, one cycle of carboplatin AUC 7 is recommended 1, 5, 2, 3.

Key evidence supporting carboplatin:

• The landmark randomized trial comparing carboplatin AUC 7 versus radiotherapy showed equivalent 5-year relapse-free survival (94.7% vs 96%, HR 1.25, p=0.37) 5
• Carboplatin causes significantly fewer contralateral germ cell tumors (2 cases vs 15 with radiotherapy, HR 0.22) 5
• Carboplatin produces less treatment-related lethargy, shorter sick leave, and likely fewer secondary malignancies compared to radiotherapy 4

Two cycles of carboplatin reduce relapse rates further (1.5% vs 5% with one cycle) but lack long-term safety data and randomized comparison 8. The NCCN panel does not currently recommend routine use of two cycles over one 8.

Carboplatin Dosing Specifics

• Dose: AUC 7, calculated using Calvert formula: Total dose (mg) = 7 × (GFR + 25) 5, 9
• GFR should be measured, not estimated
• No dose capping is necessary for patients with high creatinine clearance >125 mL/min—toxicity is not increased 10
• Administer as 15-minute infusion; no pre/post-hydration required 9

Radiotherapy: No Longer Routine

Adjuvant radiotherapy should NOT be offered as a routine option for stage I seminoma 3. It should be reserved only for highly selected patients unsuitable for systemic chemotherapy in the event of relapse 2.

Why radiotherapy has fallen out of favor:

• Increased risk of secondary malignancies (28-80% increased risk of death from non-testis cancer causes) 8
• Cardiovascular toxicity and metabolic complications 2
• Higher rate of contralateral germ cell tumors compared to carboplatin 5

If radiotherapy must be used: 20 Gy in 10 fractions (2 Gy each) to para-aortic lymph nodes only 4, 5. Do NOT include ipsilateral iliac nodes unless prior inguinal/scrotal surgery 4, 11.

Surveillance Protocol

Intensive surveillance is required, particularly in the first 3 years:

Years 1-2:

• History, physical exam, tumor markers (AFP, β-hCG, LDH): every 3-4 months 5
• Abdominal/pelvic CT: every 6 months 5
• Chest X-ray: as clinically indicated 5

Year 3:

• Clinical visits: every 6 months 5
• CT: every 6-12 months 5

Years 4-5:

• Clinical visits: annually 5
• CT: annually 5

Beyond 5 years:

• Annual clinical follow-up 5
• Late relapses can occur but are rare 4

Common pitfall: Approximately 75% of relapses occur within the first 2 years, so surveillance intensity must be highest during this period 12. CT imaging is essential—54.8% of relapses are detected by surveillance CT before becoming symptomatic 12.

Post-Carboplatin Follow-up (Less Intensive)

For patients who received adjuvant carboplatin, relapse risk after 3 years is <0.3% annually 5:

• Years 1-3: Clinical exam and markers every 3-6 months; abdominal/pelvic CT annually 5
• Beyond 3 years: Annual clinical follow-up; imaging as clinically indicated 5

Shared Decision-Making Framework

The choice between surveillance and adjuvant carboplatin must incorporate patient autonomy after thorough discussion 3:

Favor Surveillance if:

• Patient is compliant and accepts 15-20% relapse risk
• No risk factors or only one risk factor present
• Patient wants to minimize treatment exposure
• Access to reliable follow-up imaging

Favor Adjuvant Carboplatin if:

• Both risk factors present (tumor ≥4 cm AND rete testis invasion)
• Patient anxiety about relapse is high
• Compliance with intensive surveillance is questionable
• Geographic/logistic barriers to frequent follow-up
• Patient preference after informed discussion

Avoid Radiotherapy unless:

• Patient absolutely cannot receive cisplatin-based chemotherapy if relapse occurs
• Patient refuses both surveillance and carboplatin after full counseling

Critical Counseling Points

1. All three approaches achieve ~99% cure rate—the decision is about toxicity trade-offs, not survival 4
2. Surveillance requires commitment to intensive follow-up for at least 5 years 6
3. Carboplatin has minimal acute toxicity (mostly mild thrombocytopenia/leukopenia) 10
4. Radiotherapy carries long-term risks that outweigh benefits in most patients 2, 8, 3
5. Relapses on surveillance are highly curable with salvage therapy 1, 2